FDA Updates

Patients with unresectable or metastatic hepatocellular carcinoma (HCC) receiving this regimen had favorable median overall survival (23.7 months) compared with standard of care (20.6 months).

This approval marks bevacizumab-nwgd as the sixth reference product to bevacizumab (Avastin).

The approval is for those with metastatic disease or in whom surgical resection is likely to result in severe morbidity, have no satisfactory alternative treatments, or have progressed following treatment.

Data show that the system is also the most accurate continuous glucose monitor (CGM).

The approval was based on efficacy and safety data from a randomized, 3-arm, open-label phase 3 CHECKMATE-8HW trial.

The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

This action makes inebilizumab the first and only FDA-approved treatment for adults with immunoglobulin G4-related disease (IgG4-RD).

No manufacturing or safety issues were identified, but the FDA stated the new drug application did not demonstrate efficacy in adequate and well-controlled studies.

The Auto-Pure 2400 system combines liquid handling and magnetic cell isolation for efficient latent tuberculosis testing.

A phase 1/2 clinical trial will provide crucial data on the vaccine's tolerability and pave the way for future development and potential widespread use.

The antibody-drug conjugate is currently undergoing evaluation in a phase 1 trial that enrolled patients with pancreatic cancer and squamous non-small cell lung cancer (NSCLC).

Currently, BEAM-302 is undergoing a phase 1/2 clinical trial to evaluate its efficacy in patients with alpha-1 antitrypsin deficiency (AATD) who have lung disease and liver disease.

Approval of durvalumab is in combination with gemcitabine and cisplatin as neoadjuvant treatment for adults with muscle invasive bladder cancer.

Approval of fitusiran, a small interfering RNA drug, was found effective in patients with hemophilia regardless of inhibitor status.

The biosimilar is approved for all indications of the reference products, Prolia and Xgeva.

The approval fills a treatment gap for patients with this rare disease, which can severely diminish quality of life.

Patients achieved statistically significant benefits in progression-free survival and overall response rates.

Gepotidacin is indicated for female patients who are at least 12 years of age and weigh at least 40 kg with uncomplicated urinary tract infections (uUTIs) caused by certain microorganisms.

If approved, this novel monoclonal antibody therapy could become a standard of care emergency option for patients with acute myocardial infarction, which affects millions in the United States and across the world.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Exidavnemab is a novel monoclonal antibody with disease-modifying potential.

Patients with a disorder from this family of neurodevelopmental conditions face a lack of approved treatment options, making radiprodil poised to transform the treatment paradigm.